239 related articles for article (PubMed ID: 33664708)
1. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
[TBL] [Abstract][Full Text] [Related]
2. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
[TBL] [Abstract][Full Text] [Related]
3. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
[TBL] [Abstract][Full Text] [Related]
4. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation.
Peverelli E; Giardino E; Vitali E; Treppiedi D; Lania AG; Mantovani G
Horm Metab Res; 2014 Nov; 46(12):845-53. PubMed ID: 25068602
[TBL] [Abstract][Full Text] [Related]
5. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
6. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
7. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
8. Total barley maiya alkaloids inhibit prolactin secretion by acting on dopamine D2 receptor and protein kinase A targets.
Gong X; Tao J; Wang Y; Wu J; An J; Meng J; Wang X; Chen Y; Zou J
J Ethnopharmacol; 2021 Jun; 273():113994. PubMed ID: 33711439
[TBL] [Abstract][Full Text] [Related]
9. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
[TBL] [Abstract][Full Text] [Related]
10. Filamin A and DRD2 expression in corticotrophinomas.
Sickler T; Trarbach EB; Frassetto FP; Dettoni JB; Alves VAF; Fragoso MCBV; Machado MC; Cardoso EF; Bronstein MD; Glezer A
Pituitary; 2019 Apr; 22(2):163-169. PubMed ID: 30799513
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation.
Peverelli E; Giardino E; Treppiedi D; Locatelli M; Vaira V; Ferrero S; Bosari S; Lania AG; Spada A; Mantovani G
Cancer Lett; 2016 Oct; 381(2):279-86. PubMed ID: 27519461
[TBL] [Abstract][Full Text] [Related]
12. Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.
Treppiedi D; Jobin ML; Peverelli E; Giardino E; Sungkaworn T; Zabel U; Arosio M; Spada A; Mantovani G; Calebiro D
Endocrinology; 2018 Aug; 159(8):2953-2965. PubMed ID: 29931263
[TBL] [Abstract][Full Text] [Related]
13. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
[TBL] [Abstract][Full Text] [Related]
14. Absence of D2S dopamine receptor in the prolactin-secreting MMQ pituitary clone: characterization of a wild D2L receptor coupled to native transduction mechanisms.
Ventra C; Meucci O; Grimaldi M; Scorziello A; Porcellini A; Schettini G
J Mol Endocrinol; 1995 Jun; 14(3):375-89. PubMed ID: 7669227
[TBL] [Abstract][Full Text] [Related]
15. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors.
Mantovani G; Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Arosio M; Spada A; Peverelli E
Endocr Relat Cancer; 2019 Feb; 26(2):R95-R108. PubMed ID: 30589642
[TBL] [Abstract][Full Text] [Related]
16. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G
Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612
[TBL] [Abstract][Full Text] [Related]
17. A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells.
Di Muro G; Mangili F; Esposito E; Barbieri AM; Catalano R; Treppiedi D; Marra G; Nozza E; Lania AGA; Ferrante E; Locatelli M; Arosio M; Peverelli E; Mantovani G
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370829
[TBL] [Abstract][Full Text] [Related]
18. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.
Zhang S; Zhong M; Zhu H; You Q; Yuan H; Li Y
Cancer Genet; 2023 Nov; 278-279():71-78. PubMed ID: 37729778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
